Andrzej Stefan Krolewski, Ph.D., M.D.
This page shows the publications co-authored by Andrzej Krolewski and Joseph Bonventre.
High risk of ESRD in type 1 diabetes: call for action: introduction. Semin Nephrol. 2012 Sep; 32(5):405-6.
High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline. Semin Nephrol. 2012 Sep; 32(5):407-14.
Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 (HSD17B14) with Reduced Progression to End Stage Kidney Disease in Type 1 Diabetes. J Am Soc Nephrol. 2021 10; 32(10):2634-2651.
Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development. Kidney Int. 2018 05; 93(5):1198-1206.
Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease. Kidney Int. 2017 07; 92(1):258-266.
Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Care. 2017 Mar; 40(3):383-390.
Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes. Kidney Int. 2016 Feb; 89(2):459-67.
Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J Am Soc Nephrol. 2014 Oct; 25(10):2177-86.
Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney Int. 2014 May; 85(5):1214-24.
Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-ß-D-glucosaminidase. Kidney Int. 2011 Feb; 79(4):464-70.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.